T-Cell Memory Finding May Provide Key To Cancer, AIDS Vaccines

March 12, 1999

A basic science discovery concerning how part of the immune system remembers past opponents may provide the solution to a fundamental problem facing vaccines to treat AIDS or cancer. Researchers from the University of Chicago report in the March 12 issue of the journal Science that the cells that are crucial players for any vaccine against HIV-infected or cancerous cells are distressingly slow learners.

The problem, the researchers demonstrate, is that it takes several generations of intense instruction to make a lasting impression on a T cell. Creating large numbers of "memory" T cells that can recognize a trouble maker they have seen before and attack when they see it again requires prolonged continuous exposure to high levels of the intruder.

"This finding suggests that the typical approach to vaccines for treatment of cancer or AIDS is not often likely to produce the desired result," said author Philip Ashton-Rickardt, Ph.D., assistant professor of pathology at the University of Chicago. "But it also shows us how we can get around the problem."

Ashton-Rickardt's team -- including immunology graduate student Joseph Opferman and post-doctoral fellow Bertram Ober, Ph.D., all from the Gwen Knapp Center for Lupus and Immunology Research at the University of Chicago -- set out to answer a central question in immunology: Where do the T cells responsible for "remembering" a previous infection and fighting it off a second time come from?

When stimulated by an invader, T lymphocytes multiply and attack the infecting foreigner. Once they get the upper hand, most of these T cells are no longer needed and die off. A small percentage, however, survive and stand guard in case this particular invader comes back.

Immunologists have proposed two models of this process. One requires two parallel tracks for cell-killing T lymphocytes. Most of the T cells attack the foreigner then die off soon after victory. But a smaller group of T cells is preprogrammed to survive and to remember the invader. B lymphocytes, the immune cells that secrete antibodies, follow this pattern.

The competing model involves just one initial population of cell-killing T cells. Most of these cells die off after defeating the invader, but some cells survive and develop into memory cells which remain eternally vigilant for any subsequent attack.

The research team confirmed the second model. They found that it required intense, prolonged stimulation -- high levels of antigen for at least five cell divisions -- to create a significant number of memory T cells. Without strong stimulation for three to four days, few memory cells emerged. By finding the answer to this fairly basic scientific question, "we have stumbled into the world of clinical relevance," jokes Ashton-Rickardt.

"No vaccine trial to date," he said, "has been able to produce significant numbers of memory T lymphocytes, which are important in killing HIV-infected or cancerous cells. Now we know why, and we have a pretty good idea of how to change that."

The research team, working with mice, grew the memory T cells outside the body, which enabled them to challenge the cells constantly with high levels of antigen for four-to-five days -- a far more intense and prolonged confrontation than any vaccine scheme.

To test the effects, they injected the activated cells into mice without immune systems. Ten weeks later, the injected T cells were still effective, retaining all their cell-killing machinery.

"The great thing was that the memory cells were primed and ready. They required no help from other cells -- no cytokines, no co-stimulation," said Ashton-Rickardt. "They remembered and went after their targets as soon as they were exposed to them again. Although mice with normal immune systems take two or three days to mount an immune response, these memory T cells responded immediately."

The finding is particularly encouraging for those interested in vaccines as therapy for HIV infected patients, who lose their T-helper cells. Ordinarily, chemical signals from these T-helper cells are required to activate cytotoxic T cells, which are not damaged by HIV. But by growing cytotoxic T memory cells outside the body and exposing them to specially presented HIV antigens, this approach should produce effective cytotoxic T cells, which could destroy HIV-infected cells.

"We have the technology to try this already," explained Ashton-Rickardt. "Perhaps now we know how to use it."

University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.